A Randomized, Parallel-group, Double-blind Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Vilaprisan in Subjects With Uterine Fibroids
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 12 Feb 2019
At a glance
- Drugs Vilaprisan (Primary)
- Indications Uterine leiomyoma
- Focus Registrational; Therapeutic Use
- Acronyms ASTEROID 7
- Sponsors Bayer
- 04 Feb 2019 Planned End Date changed from 15 Oct 2020 to 14 Jul 2021.
- 04 Feb 2019 Planned primary completion date changed from 15 Jul 2020 to 14 Jul 2021.
- 10 Dec 2018 Status changed from recruiting to active, no longer recruiting.